Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial

Laszlo Hangody, Robert Szody, Piotr Lukasik, Wojciech Zgadzaj, Endre Lénárt, Eva Dokoupilova, Daniela Bichovsk, Agnes Berta, Gabor Vasarhelyi, Andrea Ficzere, György Hangody, Gary Stevens, Miklos Szendroi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and safety of an intraarticular injection of Cingal (Anika Therapeutics, Inc., Bedford, MA) compared with Monovisc (Anika Therapeutics, Inc., Bedford, MA) or saline for the treatment of knee osteoarthritis. Design: This multicenter, double-blind, saline-controlled clinical trial randomized subjects with knee osteoarthritis (Kellgren-Lawrence grades I-III) to a single injection of Cingal (4 mL, 88 mg hyaluronic acid [HA] plus 18 mg triamcinolone hexacetonide [TH]), Monovisc (4 mL, 88 mg HA), or saline (4 mL, 0.9%). The primary efficacy outcome was change in WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Score through 12 weeks with Cingal versus saline. Secondary outcomes included Patient and Evaluator Global Assessments, OMERACT-OARSI Responder index, and WOMAC Total, Stiffness, and Physical Function scores through 26 weeks. Results: A total of 368 patients were treated (Cingal, n = 149; Monovisc, n = 150; saline, n = 69). Cingal improvement from baseline was significantly greater than saline through 12 weeks (P = 0.0099) and 26 weeks (P = 0.0072). WOMAC Pain was reduced by 70% at 12 weeks and by 72% at 26 weeks with Cingal. Significant improvements were found in most secondary endpoints for pain and function at most time points through 26 weeks. At 1 and 3 weeks, Cingal was significantly better than Monovisc for most endpoints; Cingal and Monovisc were similar from 6 weeks through 26 weeks. A low incidence of related adverse events was reported. Conclusions: Cingal provides immediate and long-term relief of osteoarthritis-related pain, stiffness, and function, significant through 26 weeks compared to saline. Cingal had similar immediate advantages compared with HA alone, while showing benefit comparable to HA at 6 weeks and beyond.

Original languageEnglish
Pages (from-to)276-283
Number of pages8
JournalCartilage
Volume9
Issue number3
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Hyaluronic acid
Intra-Articular Injections
Knee Osteoarthritis
Controlled Clinical Trials
Hyaluronic Acid
Multicenter Studies
Placebos
Sodium
Pain
Stiffness
Ontario
Osteoarthritis
Arthritis
Therapeutics
Randomized Controlled Trials
Safety
Injections
triamcinolone hexacetonide
Incidence

Keywords

  • clinical trial
  • diagnosis
  • general
  • intraarticular delivery
  • joint involved
  • knee
  • osteoarthritis
  • therapeutic delivery

ASJC Scopus subject areas

  • Immunology and Allergy
  • Biomedical Engineering
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee : A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial. / Hangody, Laszlo; Szody, Robert; Lukasik, Piotr; Zgadzaj, Wojciech; Lénárt, Endre; Dokoupilova, Eva; Bichovsk, Daniela; Berta, Agnes; Vasarhelyi, Gabor; Ficzere, Andrea; Hangody, György; Stevens, Gary; Szendroi, Miklos.

In: Cartilage, Vol. 9, No. 3, 01.07.2018, p. 276-283.

Research output: Contribution to journalArticle

Hangody, Laszlo ; Szody, Robert ; Lukasik, Piotr ; Zgadzaj, Wojciech ; Lénárt, Endre ; Dokoupilova, Eva ; Bichovsk, Daniela ; Berta, Agnes ; Vasarhelyi, Gabor ; Ficzere, Andrea ; Hangody, György ; Stevens, Gary ; Szendroi, Miklos. / Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee : A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial. In: Cartilage. 2018 ; Vol. 9, No. 3. pp. 276-283.
@article{a65755c4f5ef47de8621d852a6fea711,
title = "Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial",
abstract = "Objective: To evaluate the efficacy and safety of an intraarticular injection of Cingal (Anika Therapeutics, Inc., Bedford, MA) compared with Monovisc (Anika Therapeutics, Inc., Bedford, MA) or saline for the treatment of knee osteoarthritis. Design: This multicenter, double-blind, saline-controlled clinical trial randomized subjects with knee osteoarthritis (Kellgren-Lawrence grades I-III) to a single injection of Cingal (4 mL, 88 mg hyaluronic acid [HA] plus 18 mg triamcinolone hexacetonide [TH]), Monovisc (4 mL, 88 mg HA), or saline (4 mL, 0.9{\%}). The primary efficacy outcome was change in WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Score through 12 weeks with Cingal versus saline. Secondary outcomes included Patient and Evaluator Global Assessments, OMERACT-OARSI Responder index, and WOMAC Total, Stiffness, and Physical Function scores through 26 weeks. Results: A total of 368 patients were treated (Cingal, n = 149; Monovisc, n = 150; saline, n = 69). Cingal improvement from baseline was significantly greater than saline through 12 weeks (P = 0.0099) and 26 weeks (P = 0.0072). WOMAC Pain was reduced by 70{\%} at 12 weeks and by 72{\%} at 26 weeks with Cingal. Significant improvements were found in most secondary endpoints for pain and function at most time points through 26 weeks. At 1 and 3 weeks, Cingal was significantly better than Monovisc for most endpoints; Cingal and Monovisc were similar from 6 weeks through 26 weeks. A low incidence of related adverse events was reported. Conclusions: Cingal provides immediate and long-term relief of osteoarthritis-related pain, stiffness, and function, significant through 26 weeks compared to saline. Cingal had similar immediate advantages compared with HA alone, while showing benefit comparable to HA at 6 weeks and beyond.",
keywords = "clinical trial, diagnosis, general, intraarticular delivery, joint involved, knee, osteoarthritis, therapeutic delivery",
author = "Laszlo Hangody and Robert Szody and Piotr Lukasik and Wojciech Zgadzaj and Endre L{\'e}n{\'a}rt and Eva Dokoupilova and Daniela Bichovsk and Agnes Berta and Gabor Vasarhelyi and Andrea Ficzere and Gy{\"o}rgy Hangody and Gary Stevens and Miklos Szendroi",
year = "2018",
month = "7",
day = "1",
doi = "10.1177/1947603517703732",
language = "English",
volume = "9",
pages = "276--283",
journal = "Cartilage",
issn = "1947-6035",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Intraarticular Injection of a Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee

T2 - A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial

AU - Hangody, Laszlo

AU - Szody, Robert

AU - Lukasik, Piotr

AU - Zgadzaj, Wojciech

AU - Lénárt, Endre

AU - Dokoupilova, Eva

AU - Bichovsk, Daniela

AU - Berta, Agnes

AU - Vasarhelyi, Gabor

AU - Ficzere, Andrea

AU - Hangody, György

AU - Stevens, Gary

AU - Szendroi, Miklos

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objective: To evaluate the efficacy and safety of an intraarticular injection of Cingal (Anika Therapeutics, Inc., Bedford, MA) compared with Monovisc (Anika Therapeutics, Inc., Bedford, MA) or saline for the treatment of knee osteoarthritis. Design: This multicenter, double-blind, saline-controlled clinical trial randomized subjects with knee osteoarthritis (Kellgren-Lawrence grades I-III) to a single injection of Cingal (4 mL, 88 mg hyaluronic acid [HA] plus 18 mg triamcinolone hexacetonide [TH]), Monovisc (4 mL, 88 mg HA), or saline (4 mL, 0.9%). The primary efficacy outcome was change in WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Score through 12 weeks with Cingal versus saline. Secondary outcomes included Patient and Evaluator Global Assessments, OMERACT-OARSI Responder index, and WOMAC Total, Stiffness, and Physical Function scores through 26 weeks. Results: A total of 368 patients were treated (Cingal, n = 149; Monovisc, n = 150; saline, n = 69). Cingal improvement from baseline was significantly greater than saline through 12 weeks (P = 0.0099) and 26 weeks (P = 0.0072). WOMAC Pain was reduced by 70% at 12 weeks and by 72% at 26 weeks with Cingal. Significant improvements were found in most secondary endpoints for pain and function at most time points through 26 weeks. At 1 and 3 weeks, Cingal was significantly better than Monovisc for most endpoints; Cingal and Monovisc were similar from 6 weeks through 26 weeks. A low incidence of related adverse events was reported. Conclusions: Cingal provides immediate and long-term relief of osteoarthritis-related pain, stiffness, and function, significant through 26 weeks compared to saline. Cingal had similar immediate advantages compared with HA alone, while showing benefit comparable to HA at 6 weeks and beyond.

AB - Objective: To evaluate the efficacy and safety of an intraarticular injection of Cingal (Anika Therapeutics, Inc., Bedford, MA) compared with Monovisc (Anika Therapeutics, Inc., Bedford, MA) or saline for the treatment of knee osteoarthritis. Design: This multicenter, double-blind, saline-controlled clinical trial randomized subjects with knee osteoarthritis (Kellgren-Lawrence grades I-III) to a single injection of Cingal (4 mL, 88 mg hyaluronic acid [HA] plus 18 mg triamcinolone hexacetonide [TH]), Monovisc (4 mL, 88 mg HA), or saline (4 mL, 0.9%). The primary efficacy outcome was change in WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Score through 12 weeks with Cingal versus saline. Secondary outcomes included Patient and Evaluator Global Assessments, OMERACT-OARSI Responder index, and WOMAC Total, Stiffness, and Physical Function scores through 26 weeks. Results: A total of 368 patients were treated (Cingal, n = 149; Monovisc, n = 150; saline, n = 69). Cingal improvement from baseline was significantly greater than saline through 12 weeks (P = 0.0099) and 26 weeks (P = 0.0072). WOMAC Pain was reduced by 70% at 12 weeks and by 72% at 26 weeks with Cingal. Significant improvements were found in most secondary endpoints for pain and function at most time points through 26 weeks. At 1 and 3 weeks, Cingal was significantly better than Monovisc for most endpoints; Cingal and Monovisc were similar from 6 weeks through 26 weeks. A low incidence of related adverse events was reported. Conclusions: Cingal provides immediate and long-term relief of osteoarthritis-related pain, stiffness, and function, significant through 26 weeks compared to saline. Cingal had similar immediate advantages compared with HA alone, while showing benefit comparable to HA at 6 weeks and beyond.

KW - clinical trial

KW - diagnosis

KW - general

KW - intraarticular delivery

KW - joint involved

KW - knee

KW - osteoarthritis

KW - therapeutic delivery

UR - http://www.scopus.com/inward/record.url?scp=85047864163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047864163&partnerID=8YFLogxK

U2 - 10.1177/1947603517703732

DO - 10.1177/1947603517703732

M3 - Article

C2 - 28535076

AN - SCOPUS:85047864163

VL - 9

SP - 276

EP - 283

JO - Cartilage

JF - Cartilage

SN - 1947-6035

IS - 3

ER -